Rebecca A Miksad
Overview
Explore the profile of Rebecca A Miksad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miksad R, Sarkar S
JCO Clin Cancer Inform
. 2025 Jan;
9():e2400214.
PMID: 39792989
No abstract available.
2.
3.
Miksad R, Calip G
JCO Clin Cancer Inform
. 2024 Jul;
8:e2400081.
PMID: 38959447
No abstract available.
4.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, et al.
JAMA Oncol
. 2024 May;
10(7):887-895.
PMID: 38753341
Importance: Two prominent organizations, the American Society of Clinical Oncology and the National Quality Forum (NQF), have developed a cancer quality metric aimed at reducing systemic anticancer therapy administration at...
5.
6.
Guadamuz J, Wang X, Ryals C, Miksad R, Snider J, Walters J, et al.
JNCI Cancer Spectr
. 2023 Sep;
7(5).
PMID: 37707536
Background: Lower neighborhood socioeconomic status (SES) is associated with suboptimal cancer care and reduced survival. Most studies examining cancer inequities across area-level socioeconomic status tend to use less granular or...
7.
Abou-Alfa G, Wang X, Parrinello C, Gossai A, Kim R, Magee K, et al.
Cancer
. 2023 Mar;
129(13):2064-2074.
PMID: 36942492
Background: Clinical trials suggest α-fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in real-world settings is unclear. Methods:...
8.
Liu Q, Mathur R, Xu Y, Torres A, Miksad R, Liu C, et al.
Clin Pharmacol Ther
. 2023 Feb;
113(5):1139-1149.
PMID: 36790088
Clinical trials have demonstrated the benefit of PD-1/PD-L1 blocking antibodies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) in defined patient populations that often exclude patients...
9.
Canavan M, Wang X, Ascha M, Miksad R, Calip G, Gross C, et al.
JAMA Oncol
. 2022 Oct;
8(12):1847-1849.
PMID: 36264566
No abstract available.
10.
Calip G, Cohen A, Rohrer R, Wang X, Wang X, Webster A, et al.
Pharmacoepidemiol Drug Saf
. 2022 Sep;
32(1):66-72.
PMID: 36111444
Purpose: Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region. Methods: This was a retrospective cohort study...